BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 33982545)

  • 1. Genetic markers for characterization and prediction of prognosis of melanoma subtypes: a 2021 update.
    Podlipnik S; Potrony M; Puig S
    Ital J Dermatol Venerol; 2021 Jun; 156(3):322-330. PubMed ID: 33982545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Increased knowledge on familial melanoma and the underlying genetics].
    Helgadottir H; Nielsen K; Höiom V
    Lakartidningen; 2017 May; 114():. PubMed ID: 28485764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma.
    Betti M; Aspesi A; Biasi A; Casalone E; Ferrante D; Ogliara P; Gironi LC; Giorgione R; Farinelli P; Grosso F; Libener R; Rosato S; Turchetti D; Maffè A; Casadio C; Ascoli V; Dianzani C; Colombo E; Piccolini E; Pavesi M; Miccoli S; Mirabelli D; Bracco C; Righi L; Boldorini R; Papotti M; Matullo G; Magnani C; Pasini B; Dianzani I
    Cancer Lett; 2016 Aug; 378(2):120-30. PubMed ID: 27181379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multigene panel sequencing of established and candidate melanoma susceptibility genes in a large cohort of Dutch non-CDKN2A/CDK4 melanoma families.
    Potjer TP; Bollen S; Grimbergen AJEM; van Doorn R; Gruis NA; van Asperen CJ; Hes FJ; van der Stoep N;
    Int J Cancer; 2019 May; 144(10):2453-2464. PubMed ID: 30414346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ocular melanoma and the BAP1 hereditary cancer syndrome: implications for the dermatologist.
    Martorano LM; Winkelmann RR; Cebulla CM; Abdel-Rahman MH; Campbell SM
    Int J Dermatol; 2014 Jun; 53(6):657-63. PubMed ID: 24697775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melanoma genetics.
    Read J; Wadt KA; Hayward NK
    J Med Genet; 2016 Jan; 53(1):1-14. PubMed ID: 26337759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. POT1 germline mutations but not TERT promoter mutations are implicated in melanoma susceptibility in a large cohort of Spanish melanoma families.
    Potrony M; Puig-Butille JA; Ribera-Sola M; Iyer V; Robles-Espinoza CD; Aguilera P; Carrera C; Malvehy J; Badenas C; Landi MT; Adams DJ; Puig S
    Br J Dermatol; 2019 Jul; 181(1):105-113. PubMed ID: 30451293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic aberrations in spitzoid melanocytic tumours and their implications for diagnosis, prognosis and therapy.
    Wiesner T; Kutzner H; Cerroni L; Mihm MC; Busam KJ; Murali R
    Pathology; 2016 Feb; 48(2):113-31. PubMed ID: 27020384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BAP1 Syndrome - Predisposition to Malignant Mesothelioma, Skin and Uveal Melanoma, Renal and Other Cancers.
    Foretová L; Navrátilová M; Svoboda M; Házová J; Vašíčková P; Sťahlová EH; Fabian P; Schneiderová M; Macháčková E
    Klin Onkol; 2019; 32(Supplementum2):118-122. PubMed ID: 31409087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Germline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study.
    Casula M; Paliogiannis P; Ayala F; De Giorgi V; Stanganelli I; Mandalà M; Colombino M; Manca A; Sini MC; Caracò C; Ascierto PA; Satta RR; ; Lissia A; Cossu A; Palmieri G;
    BMC Cancer; 2019 Aug; 19(1):772. PubMed ID: 31382929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumours associated with BAP1 mutations.
    Murali R; Wiesner T; Scolyer RA
    Pathology; 2013 Feb; 45(2):116-26. PubMed ID: 23277170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular characterization of melanoma cases in Denmark suspected of genetic predisposition.
    Wadt KA; Aoude LG; Krogh L; Sunde L; Bojesen A; Grønskov K; Wartacz N; Ek J; Tolstrup-Andersen M; Klarskov-Andersen M; Borg Å; Heegaard S; Kiilgaard JF; Hansen TV; Klein K; Jönsson G; Drzewiecki KT; Dunø M; Hayward NK; Gerdes AM
    PLoS One; 2015; 10(3):e0122662. PubMed ID: 25803691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of Genetic Testing for Cutaneous Melanoma in Countries With Low to Moderate Incidence: The Rule of 2 vs the Rule of 3.
    Delaunay J; Martin L; Bressac-de Paillerets B; Duru G; Ingster O; Thomas L
    JAMA Dermatol; 2017 Nov; 153(11):1122-1129. PubMed ID: 28903138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Recommendations for genetic testing and management of individuals genetically at-risk of cutaneous melanoma].
    Avril MF; Bahadoran P; Cabaret O; Caron O; de la Fouchardière A; Demenais F; Desjardins L; Frébourg T; Hammel P; Leccia MT; Lesueur F; Mahé E; Martin L; Maubec E; Remenieras A; Richard S; Robert C; Soufir N; Stoppa-Lyonnet D; Thomas L; Vabres P; Bressac-de Paillerets B
    Ann Dermatol Venereol; 2015 Jan; 142(1):26-36. PubMed ID: 25600792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Single Center Retrospective Review of Patients from Central Italy Tested for Melanoma Predisposition Genes.
    De Simone P; Bottillo I; Valiante M; Iorio A; De Bernardo C; Majore S; D'Angelantonio D; Valentini T; Sperduti I; Piemonte P; Eibenschutz L; Ferrari A; Carbone A; Buccini P; Paiardini A; Silipo V; Frascione P; Grammatico P
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33322357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germline mutations predisposing to melanoma.
    Toussi A; Mans N; Welborn J; Kiuru M
    J Cutan Pathol; 2020 Jul; 47(7):606-616. PubMed ID: 32249949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of melanoma susceptibility genes in high-risk patients from Central Italy.
    Pellegrini C; Maturo MG; Martorelli C; Suppa M; Antonini A; Kostaki D; Verna L; Landi MT; Peris K; Fargnoli MC
    Melanoma Res; 2017 Jun; 27(3):258-267. PubMed ID: 28146043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
    Lázár V
    Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histologic features of melanoma associated with germline mutations of CDKN2A, CDK4, and POT1 in melanoma-prone families from the United States, Italy, and Spain.
    Sargen MR; Calista D; Elder DE; Massi D; Chu EY; Potrony M; Pfeiffer RM; Carrera C; Aguilera P; Alos L; Puig S; Elenitsas R; Yang XR; Tucker MA; Landi MT; Goldstein AM
    J Am Acad Dermatol; 2020 Sep; 83(3):860-869. PubMed ID: 32283231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of Germline BAP1, CDKN2A, and CDK4 Mutations in an Australian Population-Based Sample of Cutaneous Melanoma Cases.
    Aoude LG; Gartside M; Johansson P; Palmer JM; Symmons J; Martin NG; Montgomery GW; Hayward NK
    Twin Res Hum Genet; 2015 Apr; 18(2):126-33. PubMed ID: 25787093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.